000168440 001__ 168440
000168440 005__ 20240229133609.0
000168440 0247_ $$2doi$$a10.1080/19490976.2021.1903825
000168440 0247_ $$2pmid$$apmid:33874856
000168440 0247_ $$2ISSN$$a1949-0976
000168440 0247_ $$2ISSN$$a1949-0984
000168440 0247_ $$2altmetric$$aaltmetric:104338069
000168440 037__ $$aDKFZ-2021-00914
000168440 041__ $$aEnglish
000168440 082__ $$a570
000168440 1001_ $$0P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aButt, Julia Anna$$b0$$eFirst author$$udkfz
000168440 245__ $$aAssociation of Pre-diagnostic Antibody Responses to Escherichia coli and Bacteroides fragilis Toxin Proteins with Colorectal Cancer in a European Cohort.
000168440 260__ $$aAustin, Tex.$$bLandes Bioscience$$c2021
000168440 3367_ $$2DRIVER$$aarticle
000168440 3367_ $$2DataCite$$aOutput Types/Journal article
000168440 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1663758585_25469
000168440 3367_ $$2BibTeX$$aARTICLE
000168440 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168440 3367_ $$00$$2EndNote$$aJournal Article
000168440 500__ $$a#EA:F022# /Jan-Dec 2021;13(1):1-14 / 1903825
000168440 520__ $$aExperimental evidence has implicated genotoxic Escherichia coli (E. coli) and enterotoxigenic Bacteroides fragilis (ETBF) in the development of colorectal cancer (CRC). However, evidence from epidemiological studies is sparse. We therefore assessed the association of serological markers of E. coli and ETBF exposure with odds of developing CRC in the European Prospective Investigation into Nutrition and Cancer (EPIC) study.Serum samples of incident CRC cases and matched controls (n = 442 pairs) were analyzed for immunoglobulin (Ig) A and G antibody responses to seven E. coli proteins and two isoforms of the ETBF toxin via multiplex serology. Multivariable-adjusted conditional logistic regression analyses were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association of sero-positivity to E. coli and ETBF with CRC.The IgA-positivity of any of the tested E. coli antigens was associated with higher odds of developing CRC (OR: 1.42; 95% CI: 1.05-1.91). Dual-positivity for both IgA and IgG to E. coli and ETBF was associated with >1.7-fold higher odds of developing CRC, with a significant association only for IgG (OR: 1.75; 95% CI: 1.04, 2.94). This association was more pronounced when restricted to the proximal colon cancers (OR: 2.62; 95% CI: 1.09, 6.29) compared to those of the distal colon (OR: 1.24; 95% CI: 0.51, 3.00) (pheterogeneity = 0.095). Sero-positivity to E. coli and ETBF was associated with CRC development, suggesting that co-infection of these bacterial species may contribute to colorectal carcinogenesis. These findings warrant further exploration in larger prospective studies and within different population groups.
000168440 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000168440 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000168440 650_7 $$2Other$$aColorectal cancer
000168440 650_7 $$2Other$$aEscherichia coli
000168440 650_7 $$2Other$$abacteroides fragilis
000168440 650_7 $$2Other$$aprospective
000168440 650_7 $$2Other$$aserology
000168440 7001_ $$00000-0002-0573-1852$$aJenab, Mazda$$b1
000168440 7001_ $$aWerner, Jill$$b2
000168440 7001_ $$aFedirko, Veronika$$b3
000168440 7001_ $$aWeiderpass, Elisabete$$b4
000168440 7001_ $$aDahm, Christina C$$b5
000168440 7001_ $$aTjønneland, Anne$$b6
000168440 7001_ $$aOlsen, Anja$$b7
000168440 7001_ $$aBoutron-Ruault, Marie-Christine$$b8
000168440 7001_ $$aRothwell, Joseph A$$b9
000168440 7001_ $$00000-0001-7157-419X$$aSeveri, Gianluca$$b10
000168440 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b11$$udkfz
000168440 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b12$$udkfz
000168440 7001_ $$aAleksandrova, Krasimira$$b13
000168440 7001_ $$aSchulze, Matthias$$b14
000168440 7001_ $$aPalli, Domenico$$b15
000168440 7001_ $$aPala, Valeria$$b16
000168440 7001_ $$aPanico, Salvatore$$b17
000168440 7001_ $$aTumino, Rosario$$b18
000168440 7001_ $$aSacerdote, Carlotta$$b19
000168440 7001_ $$aBueno-de-Mesquita, Bas$$b20
000168440 7001_ $$00000-0003-0817-7567$$aVan Gils, Carla H$$b21
000168440 7001_ $$aGram, Inger Torhild$$b22
000168440 7001_ $$aLukic, Marko$$b23
000168440 7001_ $$aSala, Núria$$b24
000168440 7001_ $$aSánchez Pérez, María José$$b25
000168440 7001_ $$aArdanaz, Eva$$b26
000168440 7001_ $$aChirlaque, María-Dolores$$b27
000168440 7001_ $$aPalmquist, Richard$$b28
000168440 7001_ $$aLöwenmark, Thyra$$b29
000168440 7001_ $$aTravis, Ruth C$$b30
000168440 7001_ $$aHeath, Alicia$$b31
000168440 7001_ $$aCross, Amanda J$$b32
000168440 7001_ $$aFreisling, Heinz$$b33
000168440 7001_ $$aZouiouich, Semi$$b34
000168440 7001_ $$aAglago, Elom$$b35
000168440 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b36$$udkfz
000168440 7001_ $$00000-0003-1668-8770$$aHughes, David J$$b37
000168440 773__ $$0PERI:(DE-600)2575755-6$$a10.1080/19490976.2021.1903825$$gVol. 13, no. 1, p. 1 - 14$$n1$$p1903825$$tGut microbes$$v13$$x1949-0984$$y2021
000168440 909CO $$ooai:inrepo02.dkfz.de:168440$$pVDB
000168440 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000168440 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000168440 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000168440 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b36$$kDKFZ
000168440 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000168440 9130_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000168440 9141_ $$y2021
000168440 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGUT MICROBES : 2019$$d2021-01-30
000168440 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-30
000168440 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-30
000168440 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-30
000168440 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-30
000168440 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000168440 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-30
000168440 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-30
000168440 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000168440 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-30
000168440 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bGUT MICROBES : 2019$$d2021-01-30
000168440 9201_ $$0I:(DE-He78)F022-20160331$$kF022$$lInfektionen und Krebs-Epidemiologie$$x0
000168440 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x1
000168440 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000168440 980__ $$ajournal
000168440 980__ $$aVDB
000168440 980__ $$aI:(DE-He78)F022-20160331
000168440 980__ $$aI:(DE-He78)F020-20160331
000168440 980__ $$aI:(DE-He78)C020-20160331
000168440 980__ $$aUNRESTRICTED